Detail akcie Cellectar Bioscn Rg online

Business Summary: Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Financial Summary: BRIEF: For the three months ended 31 March 2024, Cellectar Biosciences Inc revenues was not reported. Net loss increased from $8.6M to $21.6M. Higher net loss reflects General and administrative increase from $1.7M to $4.2M (expense), Reaserch and development increase of 11% to $7.3M (expense), General and administrative increase of 13% to $386K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.76 to -$0.74.